Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Heptares Therapeutics
Heptares Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Media
Heptares enters drug collaboration with Imperial
Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Research & Development
Heptares enters research and drug discovery collaboration
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, launched a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan
Research & Development
New programme focused on GPCR target implicated in brain cancer
Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine
Research & Development
Heptares plans relocation to Cambridge, UK
Heptares is planning to create a state of the art research and development facility on Granta Park to support its growth strategy
Research & Development
John Daly Lecture Award for Heptares’ co-founder
Heptares’ co-founder and Chief Scientific Officer, Fiona Marshall, receives 2017 John Daly Lecture Award in recognition of her outstanding contribution to GPCR drug discovery
Research & Development
New insights to advance drug discovery in pain, cancer and inflammation
Heptares collaboration with AstraZeneca yields novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules
Subscribe now